Hypoxia Up-regulates HIF Expression While Suppressing Cell Growth and NOTCH Activity in Leukaemia Cells.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 22 05 2019
revised: 18 06 2019
accepted: 20 06 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 8 8 2019
Statut: ppublish

Résumé

To examine the influence of hypoxia on the in vitro growth of leukaemia cells and the activity of signalling proteins to better understand the pathophysiology of leukaemia cells in human bone marrow. Six human leukaemia cell lines were cultured under normoxic or hypoxic conditions. Cell growth, recovery of clonogenic cells, and the expression and activation of various signalling proteins were examined. Hypoxia suppressed cell growth and the recovery of clonogenic cells. Moreover, hypoxia up-regulated hypoxia-inducible factor (HIF) 1α and HIF2α expression while suppressing the expression and activation of NOTCH1, mechanistic target of rapamycin kinase (mTOR) activation, and nuclear factor-kappa B (NF-κB) phosphorylation. We found that hypoxia up-regulated HIF expression while it suppressed the self-renewal capacity of leukaemia cells, NOTCH activity, and expression of its down-stream signalling molecules, which differs from previous reports mentioning that HIF activates NOTCH signalling. Our findings serve to further elucidate the in vivo pathophysiology of leukaemia cells.

Identifiants

pubmed: 31366501
pii: 39/8/4165
doi: 10.21873/anticanres.13575
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
HIF1A protein, human 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
NF-kappa B 0
NOTCH1 protein, human 0
Receptor, Notch1 0
endothelial PAS domain-containing protein 1 1B37H0967P
MTOR protein, human EC 2.7.1.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4165-4170

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Mai Itoh (M)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Yuki Okuhashi (Y)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Yusuke Takahashi (Y)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Yuri Sonoda (Y)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Salwa Mohammad (S)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Tatsuya Saito (T)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Erika Shiratori (E)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Shuji Tohda (S)

Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan tohda.mlab@tmd.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH